/Johnson%20%26%20Johnson%20logo%20on%20phone-by%20Allmy%20via%20Shutterstock.jpg)
New Brunswick, New Jersey-based Johnson & Johnson (JNJ) primarily focuses on drug discovery and manufacturing but has a diversified business model. With a market cap of $425.8 billion, the company operates through pharmaceuticals, medical devices, and consumer products divisions.
Companies worth $200 billion or more are generally described as "mega-cap stocks." JNJ fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the healthcare sector. The company’s extensive operations span numerous countries spanning the Americas, EMEA, and the Indo-Pacific.
Johnson & Johnson touched its three-year high of $181.16 on Aug. 22 and is currently trading 3.2% below that peak. Further, JNJ stock has soared 15.1% over the past three months, notably outperforming the Health Care Select Sector SPDR Fund’s (XLV) 3.8% uptick during the same time frame.
Johnson & Johnson has outperformed the healthcare sector over the long term as well. JNJ stock has gained 7% over the past 52 weeks and 21.3% on a YTD basis, compared to XLV’s 12.4% plunge over the past year and marginal 83 bps dip in 2025.
To confirm the recent upturn, JNJ stock has jumped above its 200-day and 50-day moving averages in mid-July.
Johnson & Johnson’s stock prices surged 6.2% in a single trading session following the release of its impressive Q2 results on Jul. 16. Driven by the strength and momentum of its strong product portfolio, the company’s total revenues increased 5.8% year-over-year to $23.7 billion, beating the Street expectations by a notable 3.8%. Meanwhile, its adjusted EPS dipped 1.8% year-over-year to $2.77, but surpassed the consensus estimates by 4.1%, boosting investor confidence.
Moreover, Johnson & Johnson has also outperformed its peer, AbbVie Inc.’s (ABBV) 6.4% gains over the past year and 17% surge in 2025.
JNJ stock has a consensus “Moderate Buy” rating overall. As of writing, JNJ’s mean price target of $177.36 represents a modest 1.1% upside potential. While the Street-high target of $200 suggests a notable 14% premium to current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
